BioMarin Pharmaceutical Inc. (BMRN) Balance Sheet

The sequential surge in assets from $8.6B to $11.7B reflects the Amicus deal, which also lifted goodwill from $196.2M to $655.7M. This expansion appears to be a strategic pivot toward inorganic growth, but the accompanying debt increase from $1.4B to $4.2B suggests leverage is now a key component of the balance sheet. The equity base only rose by $0.1B, indicating that the acquisition was largely debt-financed, which may pressure future returns if integration costs persist.

The D/E ratio more than doubled sequentially, signaling a strategic shift from a nearly debt-free balance sheet to one with meaningful leverage. While the absolute level remains moderate, the rapid increase warrants monitoring for refinancing risk, especially if interest rates remain elevated. The company's cash position of $874M provides a buffer, but it is only 21% of total debt, suggesting reliance on operating cash flows to service obligations.

The increase in goodwill from the Amicus acquisition introduces potential impairment risk if the acquired assets underperform. PPE has been relatively flat around $1B, suggesting the company is not heavily investing in new manufacturing capacity, which aligns with its low capital intensity. The asset mix now includes a larger proportion of intangibles, which may not be as liquid or recoverable as tangible assets, but this is typical for biotech acquisitions.

The transition to positive retained earnings is a notable milestone, reflecting cumulative profitability over the past year. However, the equity growth of only $1.2B over the period is modest relative to the asset expansion, suggesting that the acquisition was primarily debt-funded. The company has not been returning capital via dividends or buybacks, as per the cash flow statement, which may be a point of contention for investors seeking shareholder returns.

The current ratio remains healthy, but the sharp decline from 5.81 to 2.39 indicates reduced liquidity headroom. Cash levels are now at their lowest in the past ten quarters, which may limit flexibility for further investments or unexpected shocks. The company's ability to cover short-term obligations is still adequate, but the buffer against operational disruptions has narrowed, warranting close monitoring of cash generation.